• Mutation; HGNC; HGNC:3236; EGFR; Simple; p.Val769_Asp770insAlaSerVal (c.2308_2309insCCAGCGTGG) (c.2300_2308dup) (M766_A767insASV) (p.Ala767_Val769dupAlaSerVal) (A767_V769dupASV); ClinVar=VCV000177678; Zygosity=Heterozygous (PubMed=33355298).
  

PubMed=29686424; DOI=10.1038/s41591-018-0007-9; PMCID=PMC5964608
Jacqulyne P. Robichaux, Yasir Yousif Elamin, Zhi Tan, Brett W. Carter, Shu-Xing Zhang, Sheng-Wu Liu, Shuai Li, Ting Chen, Alissa Poteete, Adriana Estrada-Bernal, Anh T. Le ...Show all 24 authors... , Anna Truini, Monique B. Nilsson, Hui-Ying Sun, Emily Roarty, Sarah B. Goldberg, Julie Renee Brahmer, Mehmet Altan, Charles Lu, Vassiliki Papadimitrakopoulou, Katerina Politi, Robert C. Doebele, Kwok-Kin Wong, John Victor Heymach; Show fewer authors
Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer.
Nat. Med. 24:638-646(2018)

PubMed=33355298; DOI=10.1158/1078-0432.CCR-20-3555; PMCID=PMC7926264
Adriana Estrada-Bernal, Anh T. Le, Andrea E. Doak, Vijaya G. Tirunagaru, Shevan Silva, Matthew R. Bull, Jeffrey B. Smaill, Adam V. Patterson, Chul Kim, Stephen V. Liu, Robert C. Doebele;
Tarloxotinib is a hypoxia-activated pan-HER kinase inhibitor active against a broad range of HER-family oncogenes.
Clin. Cancer Res. 27:1463-1475(2021)